Spotlight on Neurology

Credits: 1.00 CME
SMA Horizons: What Is in the Future of SMA Management?
Claudia A. Chiriboga, MD, MPH
The France Foundation

Neurology Presentations

0.50 CME / MOC
AKH Inc., Advancing Knowledge in Healthcare
Ensuring Best Practices in Spinal Muscular Atrophy Management

Ensuring Best Practices in Spinal Muscular Atrophy Management

Start

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)™/ABIM MOC Points
Released: January 6, 2021
Expires: January 5, 2022
30 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Neurology clinicians who diagnose and manage spinal muscular atrophy (SMA) in patients.

Learning Objectives

After completing this activity, the clinician should be able to:

  • Describe the expected impact of newborn screening on the early commencement of treatment in patients with spinal muscular atrophy (SMA)
  • Employ available efficacy, safety, and tolerability data on disease-modifying treatments in pre-symptomatic and symptomatic patients with SMA
  • Apply established symptomatic and supportive care strategies in patients with SMA throughout the course of their disease

Activity Description

In this activity, a panel of experts in spinal muscular atrophy (SMA) use a series of case vignettes and clinical reflection points to emphasize the importance of early diagnosis and treatment of patients with pre-symptomatic, infantile-onset, and late-onset SMA.

Faculty

Diana P. Castro, MD (Chair)
Associate Professor, Pediatrics and Neurology
University of Texas Southwestern
Children’s Health
Dallas, TX

John Brandsema, MD
Child Neurologist and Neuromuscular Section Head
Children’s Hospital of Philadelphia
Assistant Professor, Clinical Neurology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Crystal M. Proud, MD
Neuromuscular Neurologist  
Children's Hospital of The King's Daughters
Norfolk, VA

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Diana P. Castro, MD, has affiliations with Biogen, PTC Therapeutics, ReveraGen BioPharma, Inc., Sarepta Therapeutics, Scholar Rock (Contracted Research).

John Brandsema, MD, has affiliations with AveXis, Biogen (Speakers Bureau); Audentes, AveXis, Biogen, Cytokinetics, Genentech, Momenta, NS Pharma, PTC Therapeutics, Sarepta Therapeutics, WaVe (Consulting Fees); Alexion, AveXis, Biogen, CSL Behring, Cytokinetics, Fibrogen, Pfizer, PTC Therapeutics, Sarepta Therapeutics, Summit, WaVe (Contracted Research).

Crystal M. Proud, MD, has affiliations with AveXis, Biogen (Speakers Bureau); AveXis, Biogen (Consulting Fees); AveXis, Biogen (Contracted Research).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations, has no financial relationships to disclose.

RMEI Medical Education, LLC
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.
The RMEI Medical Education planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Declaration
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points and 0 patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must complete the following steps
Step 1: Review and successfully complete the activity
Step 2: Proceed to the evaluation and provide your ABIM ID and date of birth
Step 3: MOC points will be submitted to ABIM profiles within 6-8 weeks of completion

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation form and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)™/ABIM MOC Points
Released: January 6, 2021
Expires: January 5, 2022
30 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Neurology clinicians who diagnose and manage spinal muscular atrophy (SMA) in patients.

Learning Objectives

After completing this activity, the clinician should be able to:

  • Describe the expected impact of newborn screening on the early commencement of treatment in patients with spinal muscular atrophy (SMA)
  • Employ available efficacy, safety, and tolerability data on disease-modifying treatments in pre-symptomatic and symptomatic patients with SMA
  • Apply established symptomatic and supportive care strategies in patients with SMA throughout the course of their disease

Activity Description

In this activity, a panel of experts in spinal muscular atrophy (SMA) use a series of case vignettes and clinical reflection points to emphasize the importance of early diagnosis and treatment of patients with pre-symptomatic, infantile-onset, and late-onset SMA.

Faculty

Diana P. Castro, MD (Chair)
Associate Professor, Pediatrics and Neurology
University of Texas Southwestern
Children’s Health
Dallas, TX

John Brandsema, MD
Child Neurologist and Neuromuscular Section Head
Children’s Hospital of Philadelphia
Assistant Professor, Clinical Neurology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Crystal M. Proud, MD
Neuromuscular Neurologist  
Children's Hospital of The King's Daughters
Norfolk, VA

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Diana P. Castro, MD, has affiliations with Biogen, PTC Therapeutics, ReveraGen BioPharma, Inc., Sarepta Therapeutics, Scholar Rock (Contracted Research).

John Brandsema, MD, has affiliations with AveXis, Biogen (Speakers Bureau); Audentes, AveXis, Biogen, Cytokinetics, Genentech, Momenta, NS Pharma, PTC Therapeutics, Sarepta Therapeutics, WaVe (Consulting Fees); Alexion, AveXis, Biogen, CSL Behring, Cytokinetics, Fibrogen, Pfizer, PTC Therapeutics, Sarepta Therapeutics, Summit, WaVe (Contracted Research).

Crystal M. Proud, MD, has affiliations with AveXis, Biogen (Speakers Bureau); AveXis, Biogen (Consulting Fees); AveXis, Biogen (Contracted Research).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations, has no financial relationships to disclose.

RMEI Medical Education, LLC
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.
The RMEI Medical Education planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Declaration
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points and 0 patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must complete the following steps
Step 1: Review and successfully complete the activity
Step 2: Proceed to the evaluation and provide your ABIM ID and date of birth
Step 3: MOC points will be submitted to ABIM profiles within 6-8 weeks of completion

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation form and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

0.25 CME / MOC
Vindico
Alzheimer’s Disease: Early Identification and Future Therapeutic Landscape—Current Therapies for Alzheimer’s Disease With Drs. Raymond Scott Turner and Marwan Noel Sabbagh

Alzheimer’s Disease: Early Identification and Future Therapeutic Landscape—Current Therapies for Alzheimer’s Disease With Drs. Raymond Scott Turner and Marwan Noel Sabbagh

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/ ABIM MOC
Released: December 31, 2020
Expires: December 30, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, primary care physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to examine the mechanisms of action, clinical endpoints, and latest clinical evidence regarding current and emerging agents for the treatment of patients with AD.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. More than 5 million Americans are living with AD, which accounts for 60% to 80% of all dementia. By 2050, the number of Americans living with AD is projected to rise to 14 million. Despite this significant burden, currently approved AD treatments are symptomatic drugs that do not stop or delay disease progression, with no approved disease-modifying therapy. The latest data from emerging AD treatments suggest that early identification of AD patients is critical for optimizing outcomes. Thus, neurologists, primary care physicians, and other providers who care for these patients need education on strategies for the early identification and management of patients with AD. In this podcast, expert clinicians will discuss the current available therapies for Alzheimer’s disease and the strengths and weaknesses of these therapies.

Activity Chair

Raymond Scott Turner, PhD, MD, FAAN, FANA
Professor of Neurology
Georgetown University
Washington, DC

Disclosure:
Consulting Fee: Re:Cognition

Faculty

Marwan Noel Sabbagh, MD, FAAN, CCRI
Director, Lou Ruvo Center for Brain Health – Cleveland Clinic Nevada
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Clinical Professor, Department of Neurology, UNLV
Las Vegas, NV

Disclosure:
Consulting Fee: Alzheon, Athira, Biogen, Cortexyme, Danone, Eisai, Neurotrope, Regeneron, Roche-Genentech, Stage 2 Innovations, vTv Therapeutics
Contracted Research: Keep Memory Alive Foundation, National Institute of Aging
Ownership Interest: Brain Health Inc., NeuroReserve, NeuroTau, Neurotrope, Optimal Cognitive Health Company, uMethod Health, Versanum

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, listen to the podcast, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/ ABIM MOC
Released: December 31, 2020
Expires: December 30, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, primary care physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to examine the mechanisms of action, clinical endpoints, and latest clinical evidence regarding current and emerging agents for the treatment of patients with AD.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. More than 5 million Americans are living with AD, which accounts for 60% to 80% of all dementia. By 2050, the number of Americans living with AD is projected to rise to 14 million. Despite this significant burden, currently approved AD treatments are symptomatic drugs that do not stop or delay disease progression, with no approved disease-modifying therapy. The latest data from emerging AD treatments suggest that early identification of AD patients is critical for optimizing outcomes. Thus, neurologists, primary care physicians, and other providers who care for these patients need education on strategies for the early identification and management of patients with AD. In this podcast, expert clinicians will discuss the current available therapies for Alzheimer’s disease and the strengths and weaknesses of these therapies.

Activity Chair

Raymond Scott Turner, PhD, MD, FAAN, FANA
Professor of Neurology
Georgetown University
Washington, DC

Disclosure:
Consulting Fee: Re:Cognition

Faculty

Marwan Noel Sabbagh, MD, FAAN, CCRI
Director, Lou Ruvo Center for Brain Health – Cleveland Clinic Nevada
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Clinical Professor, Department of Neurology, UNLV
Las Vegas, NV

Disclosure:
Consulting Fee: Alzheon, Athira, Biogen, Cortexyme, Danone, Eisai, Neurotrope, Regeneron, Roche-Genentech, Stage 2 Innovations, vTv Therapeutics
Contracted Research: Keep Memory Alive Foundation, National Institute of Aging
Ownership Interest: Brain Health Inc., NeuroReserve, NeuroTau, Neurotrope, Optimal Cognitive Health Company, uMethod Health, Versanum

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, listen to the podcast, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
Vindico
Alzheimer’s Disease: Early Identification and Future Therapeutic Landscape—Understanding the Pathophysiology of Alzheimer’s Disease With Drs. Raymond Scott Turner and Sharon Cohen

Alzheimer’s Disease: Early Identification and Future Therapeutic Landscape—Understanding the Pathophysiology of Alzheimer’s Disease With Drs. Raymond Scott Turner and Sharon Cohen

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/ ABIM MOC
Released: December 31, 2020
Expires: December 30, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, primary care physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to assess the current understanding of the pathophysiology of Alzheimer’s disease (AD).

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. More than 5 million Americans are living with AD, which accounts for 60% to 80% of all dementia. By 2050, the number of Americans living with AD is projected to rise to 14 million. Despite this significant burden, currently approved AD treatments are symptomatic drugs that do not stop or delay disease progression, with no approved disease-modifying therapy. The latest data from emerging AD treatments suggest that early identification of AD patients is critical for optimizing outcomes. Thus, neurologists, primary care physicians, and other providers who care for these patients need education on strategies for the early identification and management of patients with AD. In this podcast, expert clinicians will discuss the pathological hallmarks of Alzheimer’s disease and how to differentiate Alzheimer’s from other dementias.

Activity Chair

Raymond Scott Turner, PhD, MD, FAAN, FANA
Professor of Neurology
Georgetown University
Washington, DC

Disclosure:
Consulting Fee: Re:Cognition


Faculty

Sharon Cohen, MD, FRCPC
Medical Director and Principal Investigator, Toronto Memory Program
Toronto, Canada

Disclosure:
Consulting Fee: Alnylam, Biogen, Cogstate, ProMIS Neurosciences, RetiSpec
Contracted Research: AbbVie, AgeneBio, Alector, Anavex, Biogen, CCHI, Eisai, Genentech, Janssen, Lilly, RetiSpec, Roche, Vielight


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, listen to the podcast, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/ ABIM MOC
Released: December 31, 2020
Expires: December 30, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, primary care physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to assess the current understanding of the pathophysiology of Alzheimer’s disease (AD).

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. More than 5 million Americans are living with AD, which accounts for 60% to 80% of all dementia. By 2050, the number of Americans living with AD is projected to rise to 14 million. Despite this significant burden, currently approved AD treatments are symptomatic drugs that do not stop or delay disease progression, with no approved disease-modifying therapy. The latest data from emerging AD treatments suggest that early identification of AD patients is critical for optimizing outcomes. Thus, neurologists, primary care physicians, and other providers who care for these patients need education on strategies for the early identification and management of patients with AD. In this podcast, expert clinicians will discuss the pathological hallmarks of Alzheimer’s disease and how to differentiate Alzheimer’s from other dementias.

Activity Chair

Raymond Scott Turner, PhD, MD, FAAN, FANA
Professor of Neurology
Georgetown University
Washington, DC

Disclosure:
Consulting Fee: Re:Cognition


Faculty

Sharon Cohen, MD, FRCPC
Medical Director and Principal Investigator, Toronto Memory Program
Toronto, Canada

Disclosure:
Consulting Fee: Alnylam, Biogen, Cogstate, ProMIS Neurosciences, RetiSpec
Contracted Research: AbbVie, AgeneBio, Alector, Anavex, Biogen, CCHI, Eisai, Genentech, Janssen, Lilly, RetiSpec, Roche, Vielight


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, listen to the podcast, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
Vindico
Alzheimer’s Disease: Early Identification and Future Therapeutic Landscape—The Future Treatment Landscape of Alzheimer’s Disease With Drs. Raymond Scott Turner and Marwan Noel Sabbagh

Alzheimer’s Disease: Early Identification and Future Therapeutic Landscape—The Future Treatment Landscape of Alzheimer’s Disease With Drs. Raymond Scott Turner and Marwan Noel Sabbagh

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/ ABIM MOC
Released: December 31, 2020
Expires: December 30, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, primary care physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to evaluate the future treatment landscape to plan for effective patient identification and management.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. More than 5 million Americans are living with AD, which accounts for 60% to 80% of all dementia. By 2050, the number of Americans living with AD is projected to rise to 14 million. Despite this significant burden, currently approved AD treatments are symptomatic drugs that do not stop or delay disease progression, with no approved disease-modifying therapy. The latest data from emerging AD treatments suggest that early identification of AD patients is critical for optimizing outcomes. Thus, neurologists, primary care physicians, and other providers who care for these patients need education on strategies for the early identification and management of patients with AD. In this podcast, expert clinicians will discuss the future of treating Alzheimer’s disease by examining the mechanisms of action and clinical trial data of emerging agents.

Activity Chair

Raymond Scott Turner, PhD, MD, FAAN, FANA
Professor of Neurology
Georgetown University
Washington, DC

Disclosure:
Consulting Fee: Re:Cognition


Faculty

Marwan Noel Sabbagh, MD, FAAN, CCRI
Director, Lou Ruvo Center for Brain Health – Cleveland Clinic Nevada
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Clinical Professor, Department of Neurology, UNLV
Las Vegas, NV

Disclosure:
Consulting Fee: Alzheon, Athira, Biogen, Cortexyme, Danone, Eisai, Neurotrope, Regeneron, Roche-Genentech, Stage 2 Innovations, vTv Therapeutics
Contracted Research: Keep Memory Alive Foundation, National Institute of Aging
Ownership Interest: Brain Health Inc., NeuroReserve, NeuroTau, Neurotrope, Optimal Cognitive Health Company, uMethod Health, Versanum


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, listen to the podcast, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/ ABIM MOC
Released: December 31, 2020
Expires: December 30, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, primary care physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to evaluate the future treatment landscape to plan for effective patient identification and management.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. More than 5 million Americans are living with AD, which accounts for 60% to 80% of all dementia. By 2050, the number of Americans living with AD is projected to rise to 14 million. Despite this significant burden, currently approved AD treatments are symptomatic drugs that do not stop or delay disease progression, with no approved disease-modifying therapy. The latest data from emerging AD treatments suggest that early identification of AD patients is critical for optimizing outcomes. Thus, neurologists, primary care physicians, and other providers who care for these patients need education on strategies for the early identification and management of patients with AD. In this podcast, expert clinicians will discuss the future of treating Alzheimer’s disease by examining the mechanisms of action and clinical trial data of emerging agents.

Activity Chair

Raymond Scott Turner, PhD, MD, FAAN, FANA
Professor of Neurology
Georgetown University
Washington, DC

Disclosure:
Consulting Fee: Re:Cognition


Faculty

Marwan Noel Sabbagh, MD, FAAN, CCRI
Director, Lou Ruvo Center for Brain Health – Cleveland Clinic Nevada
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Clinical Professor, Department of Neurology, UNLV
Las Vegas, NV

Disclosure:
Consulting Fee: Alzheon, Athira, Biogen, Cortexyme, Danone, Eisai, Neurotrope, Regeneron, Roche-Genentech, Stage 2 Innovations, vTv Therapeutics
Contracted Research: Keep Memory Alive Foundation, National Institute of Aging
Ownership Interest: Brain Health Inc., NeuroReserve, NeuroTau, Neurotrope, Optimal Cognitive Health Company, uMethod Health, Versanum


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, listen to the podcast, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
Vindico
Alzheimer’s Disease: Early Identification and Future Therapeutic Landscape—The Critical Importance of Early Diagnosis of Alzheimer’s Disease With Drs. Raymond Scott Turner and Sharon Cohen

Alzheimer’s Disease: Early Identification and Future Therapeutic Landscape—The Critical Importance of Early Diagnosis of Alzheimer’s Disease With Drs. Raymond Scott Turner and Sharon Cohen

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/ ABIM MOC
Released: December 31, 2020
Expires: December 30, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, primary care physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to review the critical importance of diagnosing patients in the early stages of AD including the latest evidence-based diagnostic strategies and modalities.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. More than 5 million Americans are living with AD, which accounts for 60% to 80% of all dementia. By 2050, the number of Americans living with AD is projected to rise to 14 million. Despite this significant burden, currently approved AD treatments are symptomatic drugs that do not stop or delay disease progression, with no approved disease-modifying therapy. The latest data from emerging AD treatments suggest that early identification of AD patients is critical for optimizing outcomes. Thus, neurologists, primary care physicians, and other providers who care for these patients need education on strategies for the early identification and management of patients with AD. In this podcast, expert clinicians will discuss why it is important to diagnose Alzheimer’s disease early and available assessment tools to make an early diagnosis.

Activity Chair

Raymond Scott Turner, PhD, MD, FAAN, FANA
Professor of Neurology
Georgetown University
Washington, DC

Disclosure:
Consulting Fee: Re:Cognition


Faculty

Sharon Cohen, MD, FRCPC
Medical Director and Principal Investigator, Toronto Memory Program
Toronto, Canada

Disclosure:
Consulting Fee: Alnylam, Biogen, Cogstate, ProMIS Neurosciences, RetiSpec
Contracted Research: AbbVie, AgeneBio, Alector, Anavex, Biogen, CCHI, Eisai, Genentech, Janssen, Lilly, RetiSpec, Roche, Vielight


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, listen to the podcast, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/ ABIM MOC
Released: December 31, 2020
Expires: December 30, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, primary care physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to review the critical importance of diagnosing patients in the early stages of AD including the latest evidence-based diagnostic strategies and modalities.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. More than 5 million Americans are living with AD, which accounts for 60% to 80% of all dementia. By 2050, the number of Americans living with AD is projected to rise to 14 million. Despite this significant burden, currently approved AD treatments are symptomatic drugs that do not stop or delay disease progression, with no approved disease-modifying therapy. The latest data from emerging AD treatments suggest that early identification of AD patients is critical for optimizing outcomes. Thus, neurologists, primary care physicians, and other providers who care for these patients need education on strategies for the early identification and management of patients with AD. In this podcast, expert clinicians will discuss why it is important to diagnose Alzheimer’s disease early and available assessment tools to make an early diagnosis.

Activity Chair

Raymond Scott Turner, PhD, MD, FAAN, FANA
Professor of Neurology
Georgetown University
Washington, DC

Disclosure:
Consulting Fee: Re:Cognition


Faculty

Sharon Cohen, MD, FRCPC
Medical Director and Principal Investigator, Toronto Memory Program
Toronto, Canada

Disclosure:
Consulting Fee: Alnylam, Biogen, Cogstate, ProMIS Neurosciences, RetiSpec
Contracted Research: AbbVie, AgeneBio, Alector, Anavex, Biogen, CCHI, Eisai, Genentech, Janssen, Lilly, RetiSpec, Roche, Vielight


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, listen to the podcast, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.25 CME
Academy for Continued Healthcare Learning
New Horizons in Migraine Prevention: Pathways to Personalized Care with CGRPs—the Year in Review

New Horizons in Migraine Prevention: Pathways to Personalized Care with CGRPs—the Year in Review

Start

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: December 30, 2020
Expires: November 21, 2021
75 minutes to complete

Accredited By

Target Audience

This activity is intended for neurologists, headache specialists, pain specialists, NPs, PAs, and other HCPs who treat patients with migraine disorder.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Develop effective strategies for incorporating CGRP mABs into daily clinical practice
  • Formulate comprehensive management plans for migraine patients on preventative treatment
  • Review current treatment guidelines and patient eligibility for use of CGRP mABs

Activity Description

Join an expert faculty panel as they discuss incorporating anti-CGRP monoclonal antibodies into daily clinical practice for migraine prevention. This video-based session will integrate didactic presentation, a case-based panel discussion, and expert review of clinical evidence, guideline recommendations, special considerations, and real-world use.

Statement of Educational Need

Migraines represent a common, debilitating disorder that continues to be both undertreated and underdiagnosed. Ninety-five percent of chronic migraine patients do not receive appropriate diagnosis or care, and the few that do, suffer from poor long-term treatment adherence. Calcitonin gene-related peptide (CGRP) monoclonal antibodies are an emerging preventative migraine therapy class that offer benefits over traditional systemic prophylaxis. This activity will review best practices for incorporating CGRP mAbs into daily clinical practice.

Chair

Jessica Ailani, MD, FAHS, FAAN
Professor, Neurology
Director, Headache Center
Medstar Georgetown University Hospital
Washington, DC

Faculty

David W. Dodick, MD
Professor of Neurology, Department of Neurology
Mayo Clinic College of Medicine
Consultant in Neurology and Program Director, Mayo Clinic Neurology Residency Program
Director, Headache, Sports Neurology, and Concussion Programs
Mayo Clinic
Scottsdale, AZ

Lawrence C. Newman, MD, FAHS, FAAN
Professor, Neurology
NYU Grossman School of Medicine
Director, Headache Division
NYU Langone Health
New York, NY

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:

Jessica Ailani, MD, FAHS, FAAN
Consulting Agreements: Alder, Amgen, Allergan, Biohaven, Eli Lilly and Company, Impel, Neurodiem, Revance, Satsuma, Theranica, Teva, Zosano
Speakers’ Bureau: Allergan, Amgen, Biohaven, Eli Lilly and Company, Teva

David W. Dodick, MD
Board of Directors: Epien Medical
Consulting Agreements: Allergan, Amgen, Biohaven Pharmaceuticals, Cerecin, Clexio Biosciences Ltd., Ctrl M Health, Eli Lilly and Company, eNeura, Equinox Pharma, Linpharma, Lundbeck, Novartis, Impel Neuro Pharma, Nocira, Pieris Pharmaceuticals, Inc., Promius Pharma, LLC, Revance, Satsuma Pharmaceuticals, Theranica, WL Gore, XoC Pharmaceuticals, Zosano Pharma, Upjohn (Division of Pfizer)
Patent 17189376.1-1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis
Stock Options: Ctrl M Health, Epien Medical, Healint, Nocira, Theranica

Lawrence C. Newman, MD, FAHS, FAAN
Advisory Board: Allergan, Amgen, Eli Lilly and Company, Supernus, Theranica

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None 

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.

Instructions for Receiving Credit

This activity will take approximately 75 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Lundbeck.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: December 30, 2020
Expires: November 21, 2021
75 minutes to complete

Accredited By

Target Audience

This activity is intended for neurologists, headache specialists, pain specialists, NPs, PAs, and other HCPs who treat patients with migraine disorder.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Develop effective strategies for incorporating CGRP mABs into daily clinical practice
  • Formulate comprehensive management plans for migraine patients on preventative treatment
  • Review current treatment guidelines and patient eligibility for use of CGRP mABs

Activity Description

Join an expert faculty panel as they discuss incorporating anti-CGRP monoclonal antibodies into daily clinical practice for migraine prevention. This video-based session will integrate didactic presentation, a case-based panel discussion, and expert review of clinical evidence, guideline recommendations, special considerations, and real-world use.

Statement of Educational Need

Migraines represent a common, debilitating disorder that continues to be both undertreated and underdiagnosed. Ninety-five percent of chronic migraine patients do not receive appropriate diagnosis or care, and the few that do, suffer from poor long-term treatment adherence. Calcitonin gene-related peptide (CGRP) monoclonal antibodies are an emerging preventative migraine therapy class that offer benefits over traditional systemic prophylaxis. This activity will review best practices for incorporating CGRP mAbs into daily clinical practice.

Chair

Jessica Ailani, MD, FAHS, FAAN
Professor, Neurology
Director, Headache Center
Medstar Georgetown University Hospital
Washington, DC

Faculty

David W. Dodick, MD
Professor of Neurology, Department of Neurology
Mayo Clinic College of Medicine
Consultant in Neurology and Program Director, Mayo Clinic Neurology Residency Program
Director, Headache, Sports Neurology, and Concussion Programs
Mayo Clinic
Scottsdale, AZ

Lawrence C. Newman, MD, FAHS, FAAN
Professor, Neurology
NYU Grossman School of Medicine
Director, Headache Division
NYU Langone Health
New York, NY

Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:

Jessica Ailani, MD, FAHS, FAAN
Consulting Agreements: Alder, Amgen, Allergan, Biohaven, Eli Lilly and Company, Impel, Neurodiem, Revance, Satsuma, Theranica, Teva, Zosano
Speakers’ Bureau: Allergan, Amgen, Biohaven, Eli Lilly and Company, Teva

David W. Dodick, MD
Board of Directors: Epien Medical
Consulting Agreements: Allergan, Amgen, Biohaven Pharmaceuticals, Cerecin, Clexio Biosciences Ltd., Ctrl M Health, Eli Lilly and Company, eNeura, Equinox Pharma, Linpharma, Lundbeck, Novartis, Impel Neuro Pharma, Nocira, Pieris Pharmaceuticals, Inc., Promius Pharma, LLC, Revance, Satsuma Pharmaceuticals, Theranica, WL Gore, XoC Pharmaceuticals, Zosano Pharma, Upjohn (Division of Pfizer)
Patent 17189376.1-1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis
Stock Options: Ctrl M Health, Epien Medical, Healint, Nocira, Theranica

Lawrence C. Newman, MD, FAHS, FAAN
Advisory Board: Allergan, Amgen, Eli Lilly and Company, Supernus, Theranica

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None 

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.

Instructions for Receiving Credit

This activity will take approximately 75 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Lundbeck.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

1.00 CME
The France Foundation
SMA Horizons: What Is in the Future of SMA Management?
0.75
Vindico
Neuromyelitis Optica Spectrum Disorder: What’s New in Diagnosis and Management?

Neuromyelitis Optica Spectrum Disorder: What’s New in Diagnosis and Management?

Start

Neuromyelitis Optica Spectrum Disorder: What’s New in Diagnosis and Management?

Activity Details

Free CME/COPE/MOC
0.75 AMA PRA Category 1 Credit(s)™/COPE Credit(s)/ABO MOC
Released: November 30, 2020
Expires: November 29, 2021
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

This continuing education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neuro-ophthalmologists, optometrists, ophthalmologists, and other health care professionals involved in the management of patients with neuromyelitis optica spectrum disorder.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the latest understanding of the pathophysiology and burden of neuromyelitis optica spectrum disorder (NMOSD).
  • Assess the diagnostic criteria that aid in the differential diagnosis of NMOSD.
  • Evaluate the latest clinical evidence regarding the efficacy and safety of conventional and emerging therapies for the treatment and prevention of NMOSD episodes.

Activity Description

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing, autoimmune disease of the central nervous system that is characterized by inflammation in the optic nerve and spinal cord. The diagnosis of NMOSD is based on the presence of core clinical characteristics, aquaporin-4 (AQP4) antibody status, and magnetic resonance imaging allowing for a differential diagnosis. Treatment options for NMOSD have been limited but three therapies have been recently approved by the US Food and Drug Administration and others are under clinical evaluation. These approved and emerging options are changing treatment paradigms for NMOSD and enhancing clinical outcomes in these patients. Within this CME activity, experts in the field will review the latest understanding of the pathophysiology and burden of NMOSD, assess the diagnostic criteria to aid in the differential diagnosis of NMOSD, as well as evaluate the latest clinical evidence regarding the efficacy and safety of conventional and emerging therapies for the treatment and prevention of NMOSD episodes.

Agenda

Introduction

Understanding NMOSD: Burden and Pathophysiology
Michael D. DePaolis, OD, FAAO

Diagnosis of NMOSD: A Closer Look
Andrew G. Lee, MD

Treatment and Prevention of NMOSD: Assessing the New Evidence
Dean W. Wingerchuk, MD

Conclusion

Activity Chair

Andrew G. Lee, MD
Chairman of Ophthalmology
Blanton Eye Institute
Houston Methodist Hospital
Clinical Professor of Ophthalmology
University of Texas Medical Branch MD Anderson Cancer Center
Adjunct Professor of Ophthalmology
Baylor College of Medicine
Houston, TX

Disclosures: No relevant financial relationships to disclose.

Faculty

Michael D. DePaolis, OD, FAAO
Associate Professor of Clinical Ophthalmology
Flaum Eye Institute/URMedicine
Rochester, NY

Disclosures: No relevant financial relationships to disclose.

Dean Wingerchuk, MD
Professor of Neurology
Chair, Department of Neurology
Mayo Clinic
Phoenix/Scottsdale, AZ

Disclosures:
Consulting Fee: Arcus Medica, Biogen, Celgene, Genentech, MedImmune, Novartis, Reistone, TG Therapeutics, Third Rock Ventures
Contracted Research: Alexion, Terumo BCT

Reviewers:
Ashay Bhatwadekar, PhD, RPh
Disclosures:
Contracted Research: NIH-National Eye Institute

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Purdue University and Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at Purdue University and Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Purdue University is approved by the Council on Optometric Practitioner Education (COPE) as an administrator/provider of continuing education (CE).

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

This enduring material is COPE-accredited for 0.75 continuing education credits and is approved for one (1) year from the date of original release, November 30, 2020 to November 29, 2021.

COPE ID #: 70320-NO
COPE Event #: 120677

Please consult your state’s Board of Optometry to determine if the CE credit may apply toward your CE requirement for license renewal.

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Ophthalmology’s Maintenance of Certification (ABO MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting MOC credit. Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn MOC credits equivalent to the amount of CME credits claimed for the activity. The CME activity provider will submit learner completion information to the ACCME for the purpose of granting ABO MOC credits within 30 days of activity completion.

This enduring material is approved for 1 year from the date of original release, November 30, 2020 to November 29, 2021.

Instructions for Receiving Credit

To participate in this CE/CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 6 of the 8 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate immediately upon completion to learners who claim AMA PRA Category 1 Credit(s)™. Purdue University will issue a CE Certificate via email within 6-8 weeks to learners who claim COPE credits.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME/CE Questions?

Contact us at
Purdue University: Pharmacy-CECR@Purdue.edu
Vindico Medical Education: CME@VindicoCME.com

Neuromyelitis Optica Spectrum Disorder: What’s New in Diagnosis and Management?

Activity Details

Free CME/COPE/MOC
0.75 AMA PRA Category 1 Credit(s)™/COPE Credit(s)/ABO MOC
Released: November 30, 2020
Expires: November 29, 2021
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

This continuing education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neuro-ophthalmologists, optometrists, ophthalmologists, and other health care professionals involved in the management of patients with neuromyelitis optica spectrum disorder.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the latest understanding of the pathophysiology and burden of neuromyelitis optica spectrum disorder (NMOSD).
  • Assess the diagnostic criteria that aid in the differential diagnosis of NMOSD.
  • Evaluate the latest clinical evidence regarding the efficacy and safety of conventional and emerging therapies for the treatment and prevention of NMOSD episodes.

Activity Description

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing, autoimmune disease of the central nervous system that is characterized by inflammation in the optic nerve and spinal cord. The diagnosis of NMOSD is based on the presence of core clinical characteristics, aquaporin-4 (AQP4) antibody status, and magnetic resonance imaging allowing for a differential diagnosis. Treatment options for NMOSD have been limited but three therapies have been recently approved by the US Food and Drug Administration and others are under clinical evaluation. These approved and emerging options are changing treatment paradigms for NMOSD and enhancing clinical outcomes in these patients. Within this CME activity, experts in the field will review the latest understanding of the pathophysiology and burden of NMOSD, assess the diagnostic criteria to aid in the differential diagnosis of NMOSD, as well as evaluate the latest clinical evidence regarding the efficacy and safety of conventional and emerging therapies for the treatment and prevention of NMOSD episodes.

Agenda

Introduction

Understanding NMOSD: Burden and Pathophysiology
Michael D. DePaolis, OD, FAAO

Diagnosis of NMOSD: A Closer Look
Andrew G. Lee, MD

Treatment and Prevention of NMOSD: Assessing the New Evidence
Dean W. Wingerchuk, MD

Conclusion

Activity Chair

Andrew G. Lee, MD
Chairman of Ophthalmology
Blanton Eye Institute
Houston Methodist Hospital
Clinical Professor of Ophthalmology
University of Texas Medical Branch MD Anderson Cancer Center
Adjunct Professor of Ophthalmology
Baylor College of Medicine
Houston, TX

Disclosures: No relevant financial relationships to disclose.

Faculty

Michael D. DePaolis, OD, FAAO
Associate Professor of Clinical Ophthalmology
Flaum Eye Institute/URMedicine
Rochester, NY

Disclosures: No relevant financial relationships to disclose.

Dean Wingerchuk, MD
Professor of Neurology
Chair, Department of Neurology
Mayo Clinic
Phoenix/Scottsdale, AZ

Disclosures:
Consulting Fee: Arcus Medica, Biogen, Celgene, Genentech, MedImmune, Novartis, Reistone, TG Therapeutics, Third Rock Ventures
Contracted Research: Alexion, Terumo BCT

Reviewers:
Ashay Bhatwadekar, PhD, RPh
Disclosures:
Contracted Research: NIH-National Eye Institute

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Purdue University and Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at Purdue University and Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Purdue University is approved by the Council on Optometric Practitioner Education (COPE) as an administrator/provider of continuing education (CE).

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

This enduring material is COPE-accredited for 0.75 continuing education credits and is approved for one (1) year from the date of original release, November 30, 2020 to November 29, 2021.

COPE ID #: 70320-NO
COPE Event #: 120677

Please consult your state’s Board of Optometry to determine if the CE credit may apply toward your CE requirement for license renewal.

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Ophthalmology’s Maintenance of Certification (ABO MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting MOC credit. Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn MOC credits equivalent to the amount of CME credits claimed for the activity. The CME activity provider will submit learner completion information to the ACCME for the purpose of granting ABO MOC credits within 30 days of activity completion.

This enduring material is approved for 1 year from the date of original release, November 30, 2020 to November 29, 2021.

Instructions for Receiving Credit

To participate in this CE/CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 6 of the 8 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate immediately upon completion to learners who claim AMA PRA Category 1 Credit(s)™. Purdue University will issue a CE Certificate via email within 6-8 weeks to learners who claim COPE credits.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME/CE Questions?

Contact us at
Purdue University: Pharmacy-CECR@Purdue.edu
Vindico Medical Education: CME@VindicoCME.com
0.25 CME
The France Foundation
Gene Therapy for SMA: Data, Implications, and Global Perspectives — Importance of Early Diagnosis and Screening in SMA

Gene Therapy for SMA: Data, Implications, and Global Perspectives — Importance of Early Diagnosis and Screening in SMA

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: October 1, 2020
Expires: September 30, 2021
15 minutes to complete

Accredited By

Target Audience

This activity will target neurologists, pediatricians, and geneticists, as well as other health care providers who may be involved in the management of patients with SMA.

Learning Objectives

  • Explore potential implications of gene therapy for SMA

Activity Description

This activity discusses new, emerging, and targeted treatments for SMA. The activity also explores the potential clinical challenges and how this affects phenotypes over time.

Statement of Educational Need

The rapid influx of information surrounding emerging treatments for SMA means that there are critical gaps in clinician knowledge and the ability to apply it in practice, creating a need for education to support clinicians who recognize, diagnose, and/or manage patients with SMA.

Faculty

Sharon Aharoni, MD
Director of SMA Therapies,
Schneider Institute of Child Neurology Children’s Medical Center
Petach Tikva, Israel

Sharon Aharoni, MD, has participated in contract research for AveXis.


Professor Enrico Bertini
Unit of Neuromuscular and Neurodegenerative Disorders
Laboratory of Molecular Medicine
Bambino Gesu' Children's Research Hospital
Rome, Italy

Professor Enrico Bertini has no financial relationships to disclose.


Professor Aviva Fattal-Valevski
Director, Pediatric Neurology Institute
Dana Children's Hospital, Tel Aviv Medical Center
Tel Aviv, Israel

Professor Aviva Fattal-Valevski has no financial relationships to disclose.


Professor Marcondes Cavalcante França Junior
Assistant Professor of Neurology
The University of Campinas
Sao Paulo, Brazil

Professor Marcondes Cavalcante França Junior has participated in advisory boards for AveXis, Biogen, and Roche.


Professor Wolfgang Mueller-Felber
Head of Center for Pediatric Neuromuscular Disorders
and Clinical Neurophysiology
Dr. von Hauner Children’s Hospital
Munich, Germany

Professor Wolfgang Mueller-Felber has participated in scientific advisory boards for Genzyme and has received research support from GlaxoSmithKline, Lilly, and Trophos.


J. Andoni Urtizberea, MD, MSc
Attending Physician
Institut de Myologie
Paris, France

J. Andoni Urtizberea, MD, MSc, has no financial relationships to disclose.


Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 66% is required to complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form. The form provides each participant the opportunity to comment on how the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: October 1, 2020
Expires: September 30, 2021
15 minutes to complete

Accredited By

Target Audience

This activity will target neurologists, pediatricians, and geneticists, as well as other health care providers who may be involved in the management of patients with SMA.

Learning Objectives

  • Explore potential implications of gene therapy for SMA

Activity Description

This activity discusses new, emerging, and targeted treatments for SMA. The activity also explores the potential clinical challenges and how this affects phenotypes over time.

Statement of Educational Need

The rapid influx of information surrounding emerging treatments for SMA means that there are critical gaps in clinician knowledge and the ability to apply it in practice, creating a need for education to support clinicians who recognize, diagnose, and/or manage patients with SMA.

Faculty

Sharon Aharoni, MD
Director of SMA Therapies,
Schneider Institute of Child Neurology Children’s Medical Center
Petach Tikva, Israel

Sharon Aharoni, MD, has participated in contract research for AveXis.


Professor Enrico Bertini
Unit of Neuromuscular and Neurodegenerative Disorders
Laboratory of Molecular Medicine
Bambino Gesu' Children's Research Hospital
Rome, Italy

Professor Enrico Bertini has no financial relationships to disclose.


Professor Aviva Fattal-Valevski
Director, Pediatric Neurology Institute
Dana Children's Hospital, Tel Aviv Medical Center
Tel Aviv, Israel

Professor Aviva Fattal-Valevski has no financial relationships to disclose.


Professor Marcondes Cavalcante França Junior
Assistant Professor of Neurology
The University of Campinas
Sao Paulo, Brazil

Professor Marcondes Cavalcante França Junior has participated in advisory boards for AveXis, Biogen, and Roche.


Professor Wolfgang Mueller-Felber
Head of Center for Pediatric Neuromuscular Disorders
and Clinical Neurophysiology
Dr. von Hauner Children’s Hospital
Munich, Germany

Professor Wolfgang Mueller-Felber has participated in scientific advisory boards for Genzyme and has received research support from GlaxoSmithKline, Lilly, and Trophos.


J. Andoni Urtizberea, MD, MSc
Attending Physician
Institut de Myologie
Paris, France

J. Andoni Urtizberea, MD, MSc, has no financial relationships to disclose.


Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 66% is required to complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form. The form provides each participant the opportunity to comment on how the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Pages